These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 10529683

  • 1. The German National Immune Tolerance Registry, 1997 update. Study Group of German Haemophilia Centres.
    Lenk H.
    Vox Sang; 1999; 77 Suppl 1():28-30. PubMed ID: 10529683
    [No Abstract] [Full Text] [Related]

  • 2. Analysis of the North American Immune Tolerance Registry (NAITR) 1993-1997: current practice implications. ISTH Factor VIII/IX Subcommittee Members.
    DiMichele DM, Kroner BL.
    Vox Sang; 1999; 77 Suppl 1():31-2. PubMed ID: 10529684
    [No Abstract] [Full Text] [Related]

  • 3. International immune tolerance registry, 1997 update.
    Mariani G, Kroner B.
    Vox Sang; 1999; 77 Suppl 1():25-7. PubMed ID: 10529682
    [No Abstract] [Full Text] [Related]

  • 4. [Improvement in anti-hemophilic preparations and its problems. 3. Treatment of hemophilia patients with inhibitors; induction of immune tolerance by a low or intermediate dose regimen].
    Iizuka A.
    Rinsho Ketsueki; 1988 May; 29(5):640-8. PubMed ID: 3145995
    [No Abstract] [Full Text] [Related]

  • 5. Epidemiology of inhibitor development in haemophilia A patients treated with virus-inactivated plasma-derived clotting factor concentrates.
    Kreuz W, Escuriola-Ettingshausen C, Martinez-Saguer I, Kaiml M, Kornhuber B.
    Vox Sang; 1999 May; 77 Suppl 1():3-8. PubMed ID: 10529676
    [No Abstract] [Full Text] [Related]

  • 6. Immune tolerance in children with factors VIII and IX inhibitors: a single centre experience.
    Mathias M, Liesner R, Hann I, Khair K.
    Haemophilia; 2005 Jul; 11(4):340-5. PubMed ID: 16011585
    [Abstract] [Full Text] [Related]

  • 7. The maintenance of tolerance after successful immune tolerance induction in hemophilia A and B: the North American Registry. Factor VIII/IX Subcommittee of the International Society for Thrombosis and Hemostasis.
    DiMichele D, Kroner B, Factor VIII/IX Subcommittee of the International Society for Thrombosis and Hemostasis.
    Haematologica; 2000 Oct; 85(10 Suppl):40-2; discussion 42-4. PubMed ID: 11187869
    [Abstract] [Full Text] [Related]

  • 8. Regimens of factor VIII administration--continuous infusion vs. bolus.
    Berntorp E.
    Haematologica; 2000 Oct; 85(10 Suppl):69-71; discussion 71-2. PubMed ID: 11187875
    [Abstract] [Full Text] [Related]

  • 9. The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy.
    Dimichele D.
    Haemophilia; 2009 Jan; 15(1):320-8. PubMed ID: 18976249
    [Abstract] [Full Text] [Related]

  • 10. Induction of immune tolerance in hemophiliacs with inhibitors by combined treatment with i.v. IgG, cyclophosphamide and factor VIII or IX.
    Nilsson IM, Berntorp E.
    Prog Clin Biol Res; 1990 Jan; 324():69-78. PubMed ID: 2106694
    [No Abstract] [Full Text] [Related]

  • 11. [The occurrence of immunological tolerance to inhibitors of factors VIII and IX in hemophilia patients].
    Brakman GG.
    Gematol Transfuziol; 1993 Feb; 38(2):18-20. PubMed ID: 8020714
    [Abstract] [Full Text] [Related]

  • 12. Inhibitors in haemophilia: a primer.
    DiMichele DM.
    Haemophilia; 2000 Jul; 6 Suppl 1():38-40. PubMed ID: 10982266
    [No Abstract] [Full Text] [Related]

  • 13. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia.
    Mathias M, Khair K, Hann I, Liesner R.
    Br J Haematol; 2004 May; 125(3):366-8. PubMed ID: 15086418
    [Abstract] [Full Text] [Related]

  • 14. Immune tolerance induction and the treatment of hemophilia. Malmö protocol update.
    Berntorp E, Astermark J, Carlborg E.
    Haematologica; 2000 Oct; 85(10 Suppl):48-50; discussion 50-1. PubMed ID: 11187871
    [Abstract] [Full Text] [Related]

  • 15. Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF-containing plasma-derived FVIII concentrate.
    Oldenburg J, Jiménez-Yuste V, Peiró-Jordán R, Aledort LM, Santagostino E.
    Haemophilia; 2014 Jan; 20(1):83-91. PubMed ID: 24354480
    [Abstract] [Full Text] [Related]

  • 16. Immune tolerance therapy for haemophilia A patients with acquired factor VIII alloantibodies: comprehensive analysis of experience at a single institution.
    Smith MP, Spence KJ, Waters EL, Beresford-Webb R, Mitchell MJ, Cuttler J, Alhaq A, Brown SA, Savidge GF.
    Thromb Haemost; 1999 Jan; 81(1):35-8. PubMed ID: 9974371
    [Abstract] [Full Text] [Related]

  • 17. Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success.
    Mariani G, Kroner B, Immune Tolerance Study Group (ITSG).
    Haematologica; 2001 Nov; 86(11):1186-93. PubMed ID: 11694405
    [Abstract] [Full Text] [Related]

  • 18. Immune tolerance induction with a factor VIII concentrate containing von Willebrand factor (Haemoctin SDH®) in 14 patients with severe haemophilia A.
    Bidlingmaier C, Kurnik K, Escuriola-Ettingshausen C, Jager R, Klamroth R, Male C, Marosi A, Nemes L, von Stackelberg A, Kreuz W.
    Haemophilia; 2011 Sep; 17(5):e837-40. PubMed ID: 21649797
    [No Abstract] [Full Text] [Related]

  • 19. Immunogenicity and immune tolerance coagulation Factors VIII and IX.
    Rup B.
    Dev Biol (Basel); 2003 Sep; 112():55-9. PubMed ID: 12762504
    [Abstract] [Full Text] [Related]

  • 20. Prophylaxis in children with haemophilia - the Polish experience.
    Klukowska A, Urasinski T, Janik-Moszant A, Bobrowska H, Balwierz W, Woznica-Karczmarz I, Dobaczewski G, Wlazlowski M, Koltan A, Badowska W, Dakowicz L, Karolczyk G, Kostrzewska M, Korczowski B, Wasinski D, Pietrys D, Laguna P, Wysocka M.
    Haemophilia; 2014 Jan; 20(1):e108-10. PubMed ID: 24251651
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.